Local Effects After Implantation Testing for Medical Devices: ISO 10993-6 Biological Evaluation

Local effects after implantation testing, performed in accordance with ISO 10993-6, is a core biological safety study that evaluates the tissue response of medical devices and biomaterials at the site of direct contact with living tissue. Through macroscopic examination and semi-quantitative histopathological scoring, this test provides objective evidence that a device does not induce excessive inflammation, fibrosis, necrosis, or other adverse local reactions, and is a key requirement for regulatory submissions to FDA, EU MDR notified bodies, NMPA, and other global authorities.

Technical Overview

Local reaction evaluation after implantation, commonly known as implantation testing, is specified in ISO 10993-6 (Biological evaluation of medical devices — Part 6: Tests for local effects after implantation). This standard describes test methods for characterizing the biological response of mammalian tissue at the site where a medical device or biomaterial is implanted in direct contact with living tissue that is not intended to interact pharmacologically, immunologically, or metabolically with the body. The Chinese national standard GB/T 16886.6 is technically identical to ISO 10993-6 and is accepted for NMPA submissions.

The purpose of the study is to assess the local biological response to a device, including the extent and reversibility of the inflammatory response, fibrous capsule formation, tissue degeneration, and necrosis. Because the biological response is dynamic, the standard requires evaluation at multiple time points, comparing the response around the test material with the response around a control material implanted in the same animal. The difference between the two responses determines whether the test material is acceptable. Implantation testing must be planned within the framework of ISO 10993-1 (risk management-based biological evaluation), conducted in compliance with ISO 10993-2 (animal welfare requirements), and prepared according to ISO 10993-12 (sample preparation and reference materials).

• Evaluates tissue compatibility of devices intended for permanent or long-term tissue, bone, or dentin contact
• Compares local tissue response of the test article against a clinically established control material
• Uses blinded, semi-quantitative histopathological scoring of inflammation, fibrosis, and capsule formation
• Supports short-term and long-term studies, from 1 week up to 104 weeks depending on clinical contact duration
• Applicable to non-absorbable, absorbable, and combination devices with appropriate adaptation

Testing Samples

Final Product or Representative Device Sections

Whenever feasible, the test sample should be the final product in its final form, finished condition, and sterilization state, because processing residues, surface treatments, and sterilization byproducts can significantly influence local tissue response. When the complete device is too large or geometrically unsuitable for implantation, representative sections of the device containing all key materials, surface finishes, and coatings should be tested.

Standard-Shaped Material Specimens

When testing raw materials or candidate formulations, specimens are fabricated into standardized shapes to ensure consistent implantation and comparable tissue contact area. Typical configurations recommended by ISO 10993-6 include smooth-edged sheets or strips for subcutaneous implantation, cylinders or rods for intramuscular implantation, and device-shaped or machined specimens for bone implantation. All edges should be finished smoothly to avoid mechanical injury that could confound the biological response.

Absorbable and Degradable Materials

For biodegradable devices such as absorbable screws, scaffolds, sutures, and drug-eluting matrices, the study design must account for the degradation timeline. Samples are evaluated at time points spanning the degradation profile so that the tissue response to both the intact material and its degradation products can be characterized, including changes in mass, mechanical integrity, and local pH effects.

Control Materials

The test article is compared against a control material with a documented history of clinical acceptability. Commonly used negative control materials include medical-grade stainless steel, high-density polyethylene, polytetrafluoroethylene, silicone elastomer, or titanium, selected to match the physical form of the test specimen. Control specimens are implanted contralaterally in the same animal, which minimizes inter-animal variability and enables direct paired comparison of tissue responses.

Testing Items

The evaluation consists of macroscopic observation followed by detailed microscopic histopathological analysis of the tissue surrounding the implant. At the scheduled necropsy, the implantation sites are examined for discoloration, hemorrhage, encapsulation, infection, or other gross abnormalities, and the findings are documented photographically.

The excised tissue blocks containing the implant are fixed, processed, sectioned, and stained, typically with hematoxylin and eosin, with additional stains such as toluidine blue for bone sections. A board-certified veterinary pathologist performs blinded scoring of the biological response in the zone immediately surrounding the implant.

• Polymorphonuclear leukocyte (neutrophil) infiltration
• Lymphocyte, plasma cell, and macrophage infiltration
• Foreign body giant cell formation and multinucleated cell response
• Necrosis, tissue degeneration, and fatty infiltration
• Fibrosis and fibrous capsule formation, including capsule thickness measurement
• Neovascularization and hemorrhage
• Bone remodeling parameters for osseous implants, including osteoid formation and bone resorption
• Material degradation behavior, fragmentation, and particle distribution for absorbable materials

Each parameter is scored on a semi-quantitative scale defined in ISO 10993-6, and an overall biological response score is calculated for both test and control sites. Statistical comparison of the test-versus-control difference forms the scientific basis for the conclusion. For degradable materials, ISO 10993-6 also recommends supplemental scoring of degraded material and particle-related responses, aligned with the degradation assessment concepts of ISO/TR 37137.

Testing Methods

Subcutaneous Implantation

Subcutaneous implantation is used for devices contacting subcutaneous tissue, such as wound closure products, subcutaneous injection sites, implanted sensors, and dermal fillers in rodent or rabbit models. Specimens are inserted through a cannula or trocar into dorsal subcutaneous pockets, with multiple test and control implants placed at symmetrically distributed sites in the same animal to allow paired comparison.

Intramuscular Implantation

Intramuscular implantation is the most widely used screening method and is considered a sensitive model for detecting local irritation potential. Cylindrical specimens are implanted into the paravertebral muscles of mice, rats, guinea pigs, or rabbits along the long axis of the muscle fibers. Rabbits are frequently selected because the larger muscle mass accommodates several test and control implants per animal, improving statistical power while reducing animal use.

Bone Implantation

For orthopedic and dental devices contacting bone, specimens are implanted into prepared defects in the femur, tibia, or calvaria of rabbits, sheep, goats, or pigs. The surgical site dimension is standardized relative to the implant geometry so that the initial mechanical environment is comparable across animals. Evaluation includes histological assessment of new bone formation, bone-implant contact, osteointegration, and any osteolysis or fibrous interposition at the interface.

Study Duration and Time Points

Study duration is selected based on the intended clinical use of the device. Short-term studies typically use implantation periods of 1, 4, and 12 weeks in rodents, and may extend up to 24 weeks. Long-term studies exceeding 24 weeks, typically at 12, 26, 52, 78, or 104 weeks, are generally performed in larger non-rodent species such as rabbits, dogs, sheep, goats, or pigs to reflect persistent or permanent clinical exposure. Comparable periods in smaller species may be justified when scientifically appropriate.

Experimental Design and Animal Welfare

The number of animals and implants per group is justified statistically and conforms to ISO 10993-2 principles of replacement, reduction, and refinement. Procedures are performed under approved anesthesia and analgesia in accredited animal facilities, and protocols are reviewed by the institutional ethics committee. Histological evaluation is conducted under blinded conditions, and the final report documents the implantation procedure, gross observations, semi-quantitative scores, comparison with controls, and pathological conclusions. Supporting practices such as ASTM F763 and ASTM F981 provide additional guidance for screening implant materials in muscle and bone.

Applications

Implantation testing is a biological evaluation endpoint required or strongly recommended for devices that contact tissue, bone, or dentin for prolonged durations. Typical product categories include:

• Orthopedic implants: bone plates, screws, intramedullary nails, joint prostheses, spinal fixation systems, and bone graft substitutes
• Dental devices: endosseous implants, abutments, guided bone regeneration membranes, and bone filling materials
• Cardiovascular and vascular implants: stents, grafts, patches, and occluders in contact with deep tissue or vessel walls
• Soft tissue implants: hernia meshes, breast implants, sphincter devices, and soft tissue fillers
• Absorbable devices: resorbable fixation devices, sutures, adhesion barriers, and tissue engineering scaffolds
• Drug-device and biologic-device combination products where eluted substances may alter local tissue response
• Neurosurgical and ophthalmic implants intended for permanent contact with sensitive tissues

Regulatory applications include FDA 510(k) and PMA submissions, CE marking technical documentation under the EU MDR and IVDR frameworks where applicable, NMPA registration dossiers in China, PMDA submissions in Japan, and registration in numerous other jurisdictions. Data generated from these studies are integrated into the overall biological safety evaluation file required by ISO 10993-1 and the ISO 10993 series.

FAQ

What is the difference between ISO 10993-6 implantation testing and ISO 10993-23 irritation testing?

ISO 10993-23 irritation testing uses short-duration exposure models such as intracutaneous injection of extracts to screen for irritant potential, whereas ISO 10993-6 implantation testing evaluates the actual device or material placed in direct contact with living tissue for clinically relevant periods. Implantation studies capture long-term biological responses such as fibrous encapsulation, chronic inflammation, and degradation effects that short-term irritation tests cannot detect.

How are implantation periods selected?

Implantation periods are chosen to match or bracket the intended clinical contact duration of the device. Devices with limited exposure may justify short-term studies at 1 to 12 weeks, while permanent implants generally require long-term studies of 26 to 104 weeks in a large animal species. Accelerated justification for shorter durations must be scientifically rationalized within the biological evaluation plan.

Can implantation testing be waived if similar devices already exist?

Yes, under a risk-based approach consistent with ISO 10993-1, implantation testing may be omitted if the device is manufactured from identical materials, processes, and surface finishes as a clinically established predicate with documented human clinical or historical test data, and no new leachables or design changes affect tissue contact. This justification must be documented in the biological risk assessment.

Which control material should be used?

The control should be a material with a well-documented history of clinical use and an established acceptable local tissue response, such as medical-grade stainless steel, titanium, polyethylene, or silicone, selected to approximate the physical form and surface characteristics of the test specimen. When an equivalent commercial device is available, it may serve as a clinically relevant comparative control.

How is the tissue response scored and interpreted?

A veterinary pathologist performs blinded semi-quantitative scoring of defined parameters such as inflammatory cell populations, necrosis, fibrosis, and capsule thickness using the scoring scheme in ISO 10993-6. The test response is compared with the simultaneous control response; a test article is generally considered acceptable when its response does not significantly exceed that of the control material, unless the difference can be justified as clinically irrelevant.

Do absorbable devices require special considerations?

Yes. For absorbable and degradable devices, time points should cover the full degradation timeline, and additional parameters such as mass loss, material fragmentation, particle distribution, and the tissue reaction to degradation products must be evaluated. Companion chemistry and mechanical testing are often conducted in parallel to correlate changes in tissue response with the degradation state of the material.